SYK stock forecast, quote, news & analysis

Key Takeaways

• Stryker (SYK) gained roughly 12.8% over the last 30 days, rebounding from about $272 per share to near $307.
• The recovery followed a sharp early-September selloff sparked by disclosure of an unresolved manufacturing issue in its peripheral vascular business.
• A planned leadership transition—Spencer Stiles succeeding Kevin Lobo as CEO effective January 1, 2027—and a $400 million investment in CMR Surgical shaped recent sentiment.
• Analyst actions were mixed: Truist lowered its price target to $310, while Barclays, Needham, and Leerink Partners reiterated Buy ratings.
• Third-quarter 2026 results are scheduled for October 29, 2026, a key near-term catalyst for the stock.
• For additional detail, investors can review Price Targets, Earnings, and Forecast data.
• Explore Trending AI Robots to see top-performing automated trading strategies across the market.

Stryker (SYK) Company Overview and Market Position

Stryker Corporation is a global medical technology company that designs, manufactures, and markets products and services across three reporting segments: MedSurg, Neurotechnology, and Orthopaedics. Its portfolio spans surgical equipment, endoscopy and communications systems, patient handling and emergency medical equipment, neurovascular devices, and implantable devices used in joint replacement, trauma, and extremities procedures. The company's Mako robotic-arm-assisted surgery system and related enabling technologies have strengthened its position in orthopaedics and surgical robotics.

With a presence across roughly 75 countries and a market capitalization exceeding $100 billion, Stryker is one of the largest pure-play medical device companies. Investors follow the stock for its durable demand from hospital and ambulatory surgery center spending, consistent innovation pipeline, and track record of acquisitions that have broadened its product reach and competitive moat.

Stryker (SYK) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, Stryker shares climbed from a closing price of about $272.36 to roughly $307.15, a gain of approximately 12.8%. The move was not a steady advance: the stock bottomed near $272 in late September before a broad recovery lifted it back above the $300 mark in the second half of October.

Over the last quarter, the picture is more mixed. Stryker traded near $352 in late July 2026 before a steep September drawdown pushed shares below $276. Even after the recent rebound, the stock remains about 7% below its late-July closing level near $330, reflecting the lingering impact of the manufacturing disclosure rather than a fully restored trend.

What Drove SYK Stock Price in the Last 30 Days

The dominant event of the period occurred on September 8, 2026, when Stryker shares fell roughly 8.8% after company leadership indicated that a manufacturing issue—previously thought to be resolved—was still affecting inventory supply in the peripheral vascular business. The disclosure erased more than $10 billion in market value and triggered investor scrutiny, including securities-focused investigations announced by law firms, though such investigations do not establish wrongdoing.

Several subsequent developments supported the recovery. On October 6, 2026, Stryker announced a planned succession in which President and COO Spencer Stiles will succeed long-time CEO Kevin Lobo effective January 1, 2027, with Lobo transitioning to Executive Chair. Around the same time, Truist lowered its price target to $310 from $340, citing softer revenue and EPS expectations, while Barclays, Needham, and Leerink Partners reiterated Buy ratings with targets of $353 and $375. On October 12, Stryker announced a $400 million investment in CMR Surgical, gaining exclusive U.S. sales rights for the Versius surgical robotics platform and an option for full acquisition—a move viewed as reinforcing its robotics ambitions. The combination of stabilizing sentiment, positive analyst coverage, and the robotics announcement helped shares reclaim the $300 level.

What Drove SYK Stock Performance Over the Last Quarter

Stryker's quarterly trajectory reflects a shift from momentum to consolidation. The stock peaked in late July around $352 before fading through August and into September, pressured by the manufacturing disclosure and, later, the CEO succession announcement. The succession is widely seen as well-planned and low-risk, but it added near-term uncertainty during a period of already-elevated volatility in medical technology shares.

Fundamentally, Stryker continues to report solid growth. For the quarter ending June 30, 2026, the company posted revenue of $6.59 billion and net income of $1.28 billion, up from $6.02 billion and $884 million in the prior-year period. Demand trends, including Mako robotic-assisted procedures and growth in ambulatory surgery centers, remain supportive, even as the manufacturing issue and valuation concerns have kept the stock below its summer highs.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots drawn from a much larger universe. Tickeron offers hundreds of automated bots that trade thousands of tickers, but only the top-performing and most relevant strategies appear in this featured section. These bots vary widely in strategy, timeframe, and performance metrics, giving traders a way to compare approaches rather than relying on a single model. Because the section is continuously refined, it highlights strategies that are currently demonstrating strength. Investors looking to supplement their own research with data-driven signals can explore the page to see which automated strategies are gaining traction.

SYK Stock Forecast Drivers: What Investors Should Watch Next

Stryker's third-quarter 2026 earnings report, scheduled for October 29, 2026, is the most immediate catalyst. Investors will focus on revenue and margin trends, any update on the peripheral vascular manufacturing issue, and management's guidance heading into 2027. The CEO transition effective January 1, 2027, is another important milestone, as is the integration of the CMR Surgical investment and its impact on the robotics portfolio.

Broader factors to monitor include hospital capital spending and procedure volumes, competitive dynamics in orthopaedics and surgical robotics, regulatory developments, and the ongoing securities-related investigations. Analyst expectations remain generally constructive, but near-term sentiment could hinge on whether Stryker demonstrates a clear resolution to the manufacturing disruption and sustains its sales momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations